Dr Seymour talks to ecancertv about the upcoming 15th International Congress on Targeted Anticancer Therapies (TAT 2017).

She explains how the congress bridges the gap between academia and industry, as well as between Europe and North America.

The congress is unique because of how small and intimate it is, with no competing sessions, she says.

TAT is important because of the opportunities it offers for delegates from different walks to interact freely with one another and to discuss and share data, she says, and is the best place for those interested in the latest emerging data in immunotherapies, new targeted drugs and new combinations.

For more on the TAT congress, don't miss our interview with TAT 2017 president, Professor Jean-Charles Soria.